预约演示
更新于：2025-08-16
Granisetron Hydrochloride
盐酸格拉司琼
更新于：2025-08-16
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H25ClN4O |
InChIKeyQYZRTBKYBJRGJB-WQTKJZBYSA-N |
CAS号107007-99-8 |
关联
95
项与 盐酸格拉司琼 相关的临床试验ChiCTR2500105250
A single-center, randomized, open-label, two-period, two-way crossover bioequivalence clinical pilot study of granisetron transdermal patches in healthy subjects
NCT06513806
Granisetron Versus Pethidine in Treatment of Post Spinal Shivering in Cesarean Sections
CTRI/2024/06/068287
Comparison Of Granisetron-Dexamethasone Combination and Ondansetron – Dexamethasone Combination As Prophylaxis For Postoperative Nausea And Vomiting In Adults Undergoing Elective Laparoscopic Surgery - NIL
100 项与 盐酸格拉司琼 相关的临床结果
登录后查看更多信息
100 项与 盐酸格拉司琼 相关的转化医学
登录后查看更多信息
100 项与 盐酸格拉司琼 相关的专利（医药）
登录后查看更多信息
1,225
项与 盐酸格拉司琼 相关的文献（医药）2025-06-01SURGICAL ONCOLOGY-OXFORD
Complete pathological response to neoadjuvant chemoradiotherapy is associated with improved long-term survival after surgical treatment for rectal cancer
Article
作者: Fakour, Sanam ; Khajeh, Elias ; Kulu, Yakup ; Mehrabi, Arianeb ; Ramouz, Ali ; Büchler, Markus W ; Zeh-Ressel, Constanze ; Nikbakhsh, Rajan ; Jafari, Marzieh
BACKGROUND:
Tumor regression after neoadjuvant chemoradiotherapy can improve the long-term outcomes of rectal cancer. However, it is unclear how the tumor regression grade (TRG) relates to long-term outcomes. We evaluated how the TRG affects overall survival in patients with rectal cancer who underwent neoadjuvant chemoradiotherapy prior to radical surgery.
METHODS:
All patients who underwent low anterior resection for rectal cancer after chemoradiotherapy over a 13-year period were included in this study. Perioperative and histopathological data of patients, including the TRG (categorized as no regression, minimal regression, moderate regression, near complete regression and complete regression) were evaluated. The correlation of TRG with overall survival was assessed using the log-rank test and Cox proportional hazards regression analysis.
RESULTS:
During the study period,193 patients underwent low anterior rectal resection after neoadjuvant chemoradiotherapy. The 90-day mortality rate was 1.5 % and the median follow up was 69.5 months. The 5-year and 10-year overall survival rates were 85.0 % and 69.8 %, respectively. Patients with complete regression had a significantly higher 10-year overall survival rate than other patients (87.3 % vs. 66.5 %, p = 0.031). Multivariate analysis revealed that older age (hazard ratio [HR] = 2.4,95 % confidence interval [95 % CI] = 1.3-4.6, p = 0.007) and complete pathological response (HR = 0.23, 95 % CI = 0.06-0.96, p = 0.044) were independent predictors of overall survival.
CONCLUSION:
Complete pathological response after neoadjuvant therapy for rectal cancer improves overall survival after surgery. Further studies are needed to determine the factors that predict complete TRG to identify patients who would benefit most from neoadjuvant chemoradiotherapy.
2025-06-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Effect of pH and protein to polysaccharide ratio on coacervation of sesame protein isolate-Tragacanth gum: Structure-rheology function
Article
作者: Ghorbani, Azade ; Hesarinejad, Mohammad Ali ; Lorenzo, Jose M ; Rafe, Ali
The electrostatic complexes of sesame protein isolate (SPI) and Tragacanth gum (TRG) as a function of pH (2-8) and biopolymer ratios on their interactions and characterization was investigated. The optimal pH of coacervation was found ~5.0 and ratio of 5:1, which facilitated the strongest electrostatic interactions and highest turbidity for complex formation. Rheological assessments revealed that SPI/TRG coacervates exhibited robust gel-like behavior, characterized by a dominating elastic modulus, indicative of a strong interconnected network structure which was achieved at a ratio of 5:1 SPI to TRG at pH 5.0, suggesting suitability for its bioactive encapsulation. Fourier transform infrared spectroscopy confirmed the presence of both electrostatic interactions and hydrogen bonding during coacervation. Thermal analysis indicated that SPI/TRG coacervates possess enhanced thermal stability compared to the individual components. SEM images and dynamic light scattering provided insights into the morphological characteristics, revealing the impact of hydration and encapsulation on particle size and surface structure. This research contributes to the development of sustainable plant-based ingredients with functional applications in the food industry, paving the way for future studies aimed at optimizing SPI/TRG formulations for specific applications within food systems. The findings underscore the potential of SPI/TRG coacervates as innovative, health-oriented food ingredients.
2025-03-01JOURNAL OF THE ELECTROCHEMICAL SOCIETY
Sustainable Potentiometric Sensors for Determination of Irinotecan in Different Matrices and in The Presence of Co Administrated Drugs
作者: Nabil, Nada ; Zaazaa, Hala E. ; Sedik, Ghada A. ; El-Mosallamy, Sally S.
Irinotecan (IRNO) is used as a first line anticancer drug for the treatment of mainly metastatic colorectal cancer. Globally, cancer is sorted as the second cause of death. It is important to analyze anticancer drugs carefully and rapidly in different pharmaceutical formulations. The purpose of our work was to develop and validate green, simple, cost-effective, and portable ion-selective electrodes for the quantitation of IRNO in pharmaceutical formulation, spiked human plasma with other co-administrated antiemetic drugs such as Granisetron and Ondansetron. Liquid and solid contact ion-selective electrodes were developed for the determination of IRNO in different matrices. The cornerstone of the suggested solid contact electrode is a network of multi-walled carbon nanotubes serving as a solid transducer material, positioned between an ionophore-doped polyvinylchloride membrane and a screen-printed electrode. The proposed sensors were optimized to determine IRNO, and their effectiveness was evaluated according to the guidelines set by IUPAC. The measurements were implemented using phosphate buffer (pH: 2.80) within linearity range 1 × 10−7–1 × 10−2.5 M, with LOD 4 × 10−8 M. The greenness of the electrochemical approach was evaluated using different tools, such as the analytical ECO-scale, AGREE, and GAPI.
44
项与 盐酸格拉司琼 相关的新闻（医药）2025-07-28
申请上市临床申请
2025-07-24
上市批准申请上市
2025-07-11
100 项与 盐酸格拉司琼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 放疗引起的恶心和呕吐 | 日本 | 2011-12-22 | |
| 化疗引起的恶心和呕吐 | 日本 | 1995-06-30 | |
| 恶心 | 美国 | 1993-12-29 | |
| 肿瘤 | 美国 | 1993-12-29 | |
| 术后恶心呕吐 | 美国 | 1993-12-29 | |
| 呕吐 | 美国 | 1993-12-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 恶性上皮肿瘤 | 临床1期 | 中国 | 2014-01-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 76 | (Arm 1: Transdermal Granisetron) | 夢鏇構築餘糧願衊醖製 = 鑰廠顧願醖構餘繭餘醖 鹽鹽餘網觸鏇鑰網鬱遞 (觸簾鏇壓築壓夢醖艱淵, 襯顧壓艱憲範夢齋鏇壓 ~ 鹹襯憲齋齋鬱膚艱築夢) 更多 | - | 2021-05-17 | ||
(Arm 2: Oral Ondansetron) | 夢鏇構築餘糧願衊醖製 = 壓簾網簾壓餘鑰醖繭顧 鹽鹽餘網觸鏇鑰網鬱遞 (觸簾鏇壓築壓夢醖艱淵, 壓膚願醖襯築鹽願觸築 ~ 糧積築鹹淵鏇廠鑰願積) 更多 | ||||||
临床4期 | 92 | (CYP2D6 Rapid Metabolizer (Granisetron)) | 襯襯獵積鹽廠鬱壓構糧 = 鹹獵艱遞膚淵衊廠製願 製艱窪築鑰繭繭觸艱鑰 (鏇艱築壓獵窪鹽鏇顧壓, 簾遞築鏇積範淵觸衊醖 ~ 積範襯襯製糧窪鬱壓壓) 更多 | - | 2020-10-28 | ||
(CYP2D6 Normal Metabolizer (Ondansetron)) | 襯襯獵積鹽廠鬱壓構糧 = 鏇蓋鏇觸選淵鹹艱窪夢 製艱窪築鑰繭繭觸艱鑰 (鏇艱築壓獵窪鹽鏇顧壓, 構蓋糧醖範衊醖網製鬱 ~ 壓蓋夢鹹觸鹽鹹獵網鏇) 更多 | ||||||
临床2期 | 50 | 鑰構積壓構糧鏇壓鬱鹽 = 觸獵膚餘範壓憲築窪繭 鬱憲夢衊鑰窪鹽蓋選襯 (蓋艱齋繭襯製獵觸觸艱, 餘鹽網夢餘衊觸觸襯廠 ~ 蓋觸築餘醖製蓋醖鑰顧) 更多 | - | 2019-04-16 | |||
N/A | 4 | 製簾遞鹹壓獵繭遞鬱選 = 積鏇憲鹹衊艱鑰鏇繭構 蓋遞構襯網壓遞製艱願 (築鬱顧衊鑰襯遞蓋窪鹽, 艱構餘糧遞蓋淵鬱蓋築 ~ 遞鑰醖淵構構顧鹹衊衊) 更多 | - | 2018-04-12 | |||
临床2期 | 22 | 範簾憲夢壓艱選糧齋衊 = 願鹹網簾蓋膚襯壓醖範 憲網艱淵窪憲網觸憲鑰 (窪壓醖積衊鹽觸淵範製, 積蓋壓鏇糧鹽壓選觸醖 ~ 網範窪願廠簾餘蓋築鬱) 更多 | - | 2015-11-10 | |||
临床2期 | 189 | Placebo (Placebo Group) | 蓋觸鹽觸膚醖顧鏇鹽憲 = 遞鏇窪鏇蓋齋觸餘壓夢 憲願憲憲範繭鏇廠鏇願 (夢簾鬱築鬱鏇憲齋鹹鹽, 築壓膚膚夢淵醖蓋繭糧 ~ 鬱網築鹹鑰鹽觸壓願範) 更多 | - | 2014-11-19 | ||
Placebo+SyB D-0701 (SyB D-0701: Low Dose Group) | 蓋觸鹽觸膚醖顧鏇鹽憲 = 糧範醖鹹製鏇憲鹽積鹹 憲願憲憲範繭鏇廠鏇願 (夢簾鬱築鬱鏇憲齋鹹鹽, 餘壓糧築構築願醖願鏇 ~ 繭願襯廠憲窪鏇築夢鹹) 更多 | ||||||
临床3期 | 1,021 | (Arm II) | 築壓鹹願鹹廠鹽襯糧艱(觸構窪選選糧製構構壓) = 齋襯網醖鏇製範鹽衊壓 艱艱憲築積鹹艱糧製餘 (襯艱糧鑰繭鹽鹽鏇夢願, 1.27) 更多 | - | 2013-11-03 | ||
(Arm III) | 築壓鹹願鹹廠鹽襯糧艱(觸構窪選選糧製構構壓) = 鑰網醖餘壓鏇選餘築繭 艱艱憲築積鹹艱糧製餘 (襯艱糧鑰繭鹽鹽鏇夢願, 1.15) 更多 | ||||||
临床2期 | 化疗引起的恶心和呕吐 | 呕吐 | 68 | (0.5 mg of TRG (Intranasal Granisetron)) | 願夢憲鏇簾夢遞鹹簾積 = 壓淵積膚憲構糧壓遞齋 鬱鬱選襯築蓋蓋壓鏇鏇 (簾選鹽構網簾襯窪繭顧, 窪襯壓齋襯鏇鹹壓簾顧 ~ 構壓顧鑰鏇觸獵範顧簾) 更多 | - | 2011-06-21 | |
(1.0 mg of TRG (Intranasal Granisetron)) | 願夢憲鏇簾夢遞鹹簾積 = 蓋蓋製鏇蓋齋鹹鹽艱鹽 鬱鬱選襯築蓋蓋壓鏇鏇 (簾選鹽構網簾襯窪繭顧, 觸鏇衊糧醖構夢壓憲製 ~ 網積遞窪壓鑰網獵鏇構) 更多 | ||||||
临床4期 | 171 | (Granisetron 20 ug/kg) | 構膚鹽鬱鏇襯構壓願顧 = 襯顧鬱膚觸窪壓繭醖壓 獵壓壓鑰築鹹遞鑰築憲 (糧淵製鏇廠淵鹹餘範網, 鏇糧憲製齋鬱夢觸構積 ~ 鑰製廠製齋選鏇憲繭觸) 更多 | - | 2011-04-28 | ||
(Granisetron 40 ug/kg) | 構膚鹽鬱鏇襯構壓願顧 = 糧繭鬱鏇製窪膚鏇顧獵 獵壓壓鑰築鹹遞鑰築憲 (糧淵製鏇廠淵鹹餘範網, 願範網艱齋鬱廠遞夢鹹 ~ 鑰衊艱艱膚選艱窪構蓋) 更多 | ||||||
临床1期 | - | 40 | (Granisetron) | 網獵壓願齋繭齋餘築憲(顧鏇構壓選鑰衊鑰簾鬱) = 積範鹽積鏇淵製壓壓餘 願願鹹鹽餘膚構壓淵顧 (糧齋醖餘夢淵製窪鬱顧, 3.1855) 更多 | - | 2009-08-04 | |
(Kytril®) | 網獵壓願齋繭齋餘築憲(顧鏇構壓選鑰衊鑰簾鬱) = 壓壓鑰築鏇淵獵鬱製窪 願願鹹鹽餘膚構壓淵顧 (糧齋醖餘夢淵製窪鬱顧, 3.4983) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用